Generate Biomedicines Inc (NASDAQ:GENB) Receives Consensus Rating of “Moderate Buy” from Analysts

Generate Biomedicines Inc (NASDAQ:GENB) has received an average recommendation of “Moderate Buy” from the seven research firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $25.00.

GENB has been the subject of several recent research reports. Morgan Stanley initiated coverage on shares of Generate Biomedicines in a research report on Tuesday, March 24th. They issued an “overweight” rating and a $20.00 price target for the company. The Goldman Sachs Group initiated coverage on shares of Generate Biomedicines in a research report on Tuesday, March 24th. They set a “buy” rating and a $26.00 price objective for the company. Piper Sandler initiated coverage on shares of Generate Biomedicines in a research report on Tuesday, March 24th. They set an “overweight” rating and a $24.00 price objective for the company. Zacks Research raised shares of Generate Biomedicines to a “hold” rating in a research report on Wednesday, March 25th. Finally, Cantor Fitzgerald assumed coverage on shares of Generate Biomedicines in a research report on Tuesday, March 24th. They set an “overweight” rating for the company.

Generate Biomedicines Price Performance

Generate Biomedicines stock opened at $15.49 on Wednesday. Generate Biomedicines has a fifty-two week low of $11.00 and a fifty-two week high of $15.89. The firm has a 50 day moving average of $12.74.

Generate Biomedicines (NASDAQ:GENB) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($1.07) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.59).

Key Stories Impacting Generate Biomedicines

Here are the key news stories impacting Generate Biomedicines this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and a $25 price target on Generate Biomedicines, which can support investor confidence even though the firm trimmed some near-term earnings forecasts.
• Positive Sentiment: HC Wainwright raised its Q3 2026 EPS estimate for Generate Biomedicines, suggesting slightly better expectations for that period. Article Title
• Neutral Sentiment: The company was also the subject of an institutional holdings update, but the filing does not provide a clear signal by itself on whether institutions were accumulating or reducing shares. Article Title
• Negative Sentiment: HC Wainwright cut several EPS estimates for 2026 and 2027, including Q2 2026, Q4 2026, Q1 2027, Q2 2027, Q3 2027, Q4 2027, FY2026, and FY2027, which suggests analysts still expect ongoing losses and some near-term pressure on profitability.
• Negative Sentiment: Generate Biomedicines previously reported a wider-than-expected quarterly loss, missing EPS estimates, which continues to weigh on the stock’s fundamental outlook.

Generate Biomedicines Company Profile

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.